Passage Bio Inc PASG

NAS: PASG | ISIN: US7027121000 1/05/2024

1,350 USD (+4,65%)

(+4,65%) 1/05/2024

Toon enkel gratis nieuws

22 maart 2021 · Passage Bio Appoints Eliseo O. Salinas, M.D., MSc, as Chief Research & Development Officer · Persbericht

8 maart 2021 · U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders · Persbericht

3 maart 2021 · Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights · Persbericht

2 maart 2021 · Passage Bio to Participate in Upcoming March Investor Conferences · Persbericht

24 februari 2021 · Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021 · Persbericht

19 februari 2021 · Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors · Persbericht

8 februari 2021 · FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options · Persbericht

22 januari 2021 · Passage Bio Announces Pricing of Public Offering · Persbericht

19 januari 2021 · Passage Bio Announces Launch of Proposed Public Offering · Persbericht

4 januari 2021 · Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

4 januari 2021 · Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe